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Abstract
Objectives Our objectives were to investigate the cost
effectiveness of apixaban, rivaroxaban, and dabigatran
compared with coumarin derivatives for stroke prevention
in patients with atrial fibrillation in a country with spe-
cialized anticoagulation clinics (the Netherlands) and in a
country without these clinics (the UK).
Methods A decision-analytic Markov model was used to
analyse the cost effectiveness of apixaban, rivaroxaban,
and dabigatran compared with coumarin derivatives in the
Netherlands and the UK over a lifetime horizon.
Results In the Netherlands, the use of rivaroxaban, apixaban,
or dabigatran increased health by 0.166, 0.365, and 0.374
quality-adjusted life-years (QALYs) compared with coumarin
derivatives, but also increased costs by €5,681, €4,754, and
€5,465, respectively. The incremental cost-effectiveness ratios
(ICERs) were €34,248, €13,024, and €14,626 per QALY
gained. In the UK, health was increased by 0.302, 0.455, and
0.461 QALYs, and the incremental costs were similar for all
three new oral anticoagulants (€5,118–5,217). The ICERs
varied from €11,172 to 16,949 per QALY gained. In the
Netherlands, apixaban had the highest chance (37 %) of being
cost effective at a threshold of €20,000; in the UK, this chance
was 41 % for dabigatran. The quality of care, reflected in time
in therapeutic range, had an important influence on the ICER.
Conclusions Apixaban, rivaroxaban, and dabigatran are
cost-effective alternatives to coumarin derivatives in the UK,
while in the Netherlands, only apixaban and dabigatran could
be considered cost effective. The cost effectiveness of the
new oral anticoagulants is largely dependent on the setting
and quality of local anticoagulant care facilities.
Key Points
New oral anticoagulants such as apixaban,
rivaroxaban, and dabigatran likely result in higher
quality-adjusted life-years (QALY) if compared with
coumarin anticoagulants in the Netherlands and the
UK, but at increased treatment costs.
Compared with coumarin derivatives, all new oral
anticoagulants could be considered cost effective in
both the Netherlands and the UK, except rivaroxaban
in the Netherlands.
In the Netherlands, apixaban had the highest chance
of being cost effective at a willingness-to-pay
threshold of €20,000 per QALY gained; in the UK,
dabigatran had the highest chance of being cost
effective at this threshold.
The cost effectiveness of new oral anticoagulants is
largely dependent on the setting and quality of local
anticoagulant care facilities.
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1 Introduction
Patients with atrial fibrillation (AF) are at increased risk of
stroke and other thromboembolic events. Therefore, an
anticoagulant is often indicated to decrease this risk [1].
Vitamin K antagonists (or coumarin derivatives) have been
used for many years as oral anticoagulants for stroke and
systemic embolism (SE) prevention in patients with AF.
These drugs have a small therapeutic window and a large
inter-individual and intra-individual variability in dose
response. Frequent monitoring of the anticoagulant effect
(expressed as international normalised ratio [INR]) is
therefore required [2]. Recently, new oral anticoagulants
have become available for the prevention of stroke and SE
in patients with AF. These drugs do not require such
monitoring and have been shown in randomized controlled
trials to be non-inferior or even superior to warfarin in the
prevention of stroke and SE [3–6].
Dabigatran is a direct thrombin inhibitor and, at a
dose of 150 mg, this anticoagulant is associated with a
lower rate of stroke and SE and a similar bleeding rate
if compared with warfarin [3, 4]. An increased risk of
myocardial infarction (MI) was seen in dabigatran users
[3], although this difference was not statistically sig-
nificant in a re-analysis after identification of additional
events [4]. Apixaban is a factor Xa inhibitor and was
shown to decrease the risk of stroke and SE as well as
the risk of bleeding [5]. Another factor Xa inhibitor,
rivaroxaban, was non-inferior to warfarin for the pre-
vention of stroke and SE, and fewer intracranial or fatal
bleeding events occurred in patients using this drug [6].
The risk of gastrointestinal bleeding was increased in
rivaroxaban users and in dabigatran users [7, 8]. All
three new oral anticoagulant drugs are considered useful
alternatives to warfarin [7]. However, since the costs of
these new drugs are considerably higher than the costs
of coumarins, it is important to investigate their cost
effectiveness carefully.
The cost effectiveness of dabigatran, apixaban, and
rivaroxaban has been investigated in several studies, and all
three were shown to be cost effective when systematically
reviewed [9, 10]. When the quality of the warfarin treat-
ment is higher (a higher percentage of time is spent in the
therapeutic INR range), the chance that dabigatran is cost
effective is lower. Because the quality of the treatment with
coumarin derivatives varies across different countries and
different healthcare settings, the cost effectiveness of the
new oral anticoagulants needs to be investigated in dif-
ferent settings [11]. In the Netherlands, treatment with
coumarin derivatives is monitored and guided by specia-
lised anticoagulation clinics. The percentage time patients
spent in the therapeutic INR range in this country is
76–79 % for patients using short- or long-term (2 months
to lifetime) acenocoumarol, which is the most frequently
used coumarin (approximately 80 % of the cases; phen-
procoumon is used in the remaining cases) in the Nether-
lands [12]. In the UK, warfarin is most frequently used, and
most of the warfarin users are treated by general practi-
tioners [13]. The percentage time spent in the therapeutic
INR range is lower than in the Netherlands; one estimate
was approximately 63 % [14]. The aim of this study is
therefore to investigate the cost effectiveness of apixaban,
rivaroxaban, and dabigatran compared with coumarin
derivatives in a country with specialized anticoagulation
clinics (the Netherlands) and in a country without these
clinics (the UK).
2 Methods
2.1 Model Structure
A decision-analytic Markov model was used to analyse the
cost effectiveness of the three new oral anticoagulants
(apixaban, rivaroxaban, and dabigatran) compared with
coumarin derivatives. The model was developed using
TreeAge software (TreeAge Pro 2012) and Microsoft
Excel. The base-case analysis consisted of a hypothetical
cohort of patients with AF, aged 70 years, initiating oral
anticoagulant therapy.
Figure 1 shows the decision tree with the four treatment
options. The decision-analytic Markov model consisted of
nine health states: healthy with AF, ischaemic stroke (IS),
transient ischaemic attack (TIA), MI, SE, intracranial
hemorrhage (ICH), extracranial hemorrhage (ECH), dis-
ability, and death. All patients entered the model in the
‘healthy with AF’ state and could move to one of the other
states at monthly intervals. Patients with an IS had a 37 %
chance of dying and 32 % chance of disability [5, 6]. The
chance that an ICH would be disabling was 50 %, and that
it would be fatal was 44 % [12, 16]. MI and ECH were
fatal in 16 and 7 % of the cases, respectively [12, 17, 18].
We assumed a similar percentage of fatal cases (7 %) in SE
as in ECH and a mortality rate of 5.6 % in patients in the
disability state [19]. Age-specific mortality rates were
taken into account for all patients using UK- and the
Netherlands-specific life tables [20, 21], excluding cere-
brovascular deaths [22] (see Table S1 in the electronic
supplementary material [ESM]). Input parameters of the
model for both the Netherlands and the UK are shown in
Table 1.
2.2 Clinical Event Rates
Annual rates of clinical events of the new oral anticoagu-
lants were derived from three large randomized controlled
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trials, because these trials provide the most reliable and
exhaustive data on events with new oral anticoagulants
currently available. Data from the ARISTOTLE trial were
used for event rates of apixaban at a dose of 5 mg twice
daily [5], data from the ROCKET-AF trial for rivaroxaban
20 mg once daily [6], and from the RE-LY trial for da-
bigatran 150 mg twice daily [3, 4]. The indirect compari-
son method by Bucher et al. [23] was used to adjust for
differences in baseline risks between the three trials.
Hazard ratios and their 95 % confidence intervals for
clinical events with rivaroxaban and dabigatran versus
apixaban were calculated and used to provide adjusted
baseline risks for rivaroxaban and dabigatran. More detail
on this method and the hazard ratios used are provided in
Table S2 in the ESM.
To correct for differences in quality of coumarin anti-
coagulant care, the rates of clinical events of coumarin
derivatives were not taken from the clinical trials
mentioned above, but based on the time spent in the ther-
apeutic INR range. The risks of thromboembolic and
hemorrhagic events associated with different INR ranges
were derived from a meta-analysis by Oake et al. [24]. In
this meta-analysis, the risk of events was calculated based
on 19 studies, including randomized trials as well as
observational studies on warfarin, acenocoumarol, or
phenprocoumon. The proportion of thromboembolic events
that were stroke, MI, or SE and the proportion of hemor-
rhagic events that were intracranial or extracranial were
derived from the warfarin arms of the three trials of the
new oral anticoagulants (weighted average) [3–6]. As in
previous cost-effectiveness studies, we assumed that 28 %
of ischemic strokes were TIA [25, 26]. More detail on the
calculation of event rates for coumarin derivatives is pro-
vided in Tables S3 and S4 in the ESM. In our model, we
used a percentage time spent in the target range of 76 % for
the Netherlands and 63 % for the UK after the initiation
Fig. 1 Schematic representation of the decision tree and Markov model. Patients initiating oral anticoagulant therapy can be treated by one of
the four drugs with different chances of developing adverse events
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period (2 months) [12, 14]. In the first month of treatment,
this percentage was 50 % (unpublished data [27]). During
the first 2 months, 75 % of the out-of-range INRs were
sub-therapeutic (INR \2) and, after the initiation period,
out-of-range INRs were more often supra-therapeutic
(70 % INR [3) (unpublished data [27]). The percentages
of time spent in the different INR ranges were then mul-
tiplied by the risk of events associated with these ranges
[24] to calculate the incidence of thromboembolic and
hemorrhagic events in every cycle. Patients using coumarin
anticoagulants did not undergo pharmacogenetic testing.
Patients receiving either one of the new oral anticoagulants
or coumarin therapy were assumed to switch to aspirin
after an ICH [1]. The annual rates of clinical events of the
different treatment options are shown in Table S3 of the
ESM.
2.3 Quality of Life and Costs
The baseline quality of life in our model was 0.81 for
patients with AF [28]. A decrement of 0.013 was applied
for coumarin use and a decrement of 0.006 for apixaban,
rivaroxaban, or dabigatran use. Decrements were also
ascribed when patients experienced an adverse event.
Table 1 shows quality-adjusted life-year (QALY) values
and decrements for the different health states.
The frequency of INR measurements varied from 15.7 to
25.4 per year, with a median of 21.4 in Dutch anticoagulant
clinics [12], and has been estimated to be in the range of
8–12 per year (we assumed an average of ten per year) in
the UK [29]. The frequency of measurements in the
Netherlands is higher, probably because a care system with
many anticoagulant clinics exists in this country, so that
patients can be seen frequently in a clinic close to their
home, while in the UK it is not feasible for patients travel
to the hospital that often. Also, in the UK, each hospital has
its own protocol for the monitoring patients, while in the
Netherlands, all anticoagulant clinics work according to the
same protocol. We assumed four extra measurements in the
first month and one extra measurement after an adverse
event. Costs of an INR measurement were derived from the
Dutch healthcare authority tariff and from a report of the
Table 1 Model input parameters for both the Netherlands and the UK
Parameter Base case Range Source Distribution
Age at start of treatment 70 60–80a a Normal
Outcome of events (if occurring) %
Fatal stroke 37 33–41c [5, 6] Dirichlet
Disabling stroke 32 28–36c [5, 6] Dirichlet
Fatal transient ischemic attack 0 – a –
Fatal systemic embolism 7 5.6–8.4b a Beta
Fatal myocardial infarction 16 13–19b [17, 18] Beta
Fatal intracranial hemorrhage 44 40–48c [12] Dirichlet
Disabling intracranial hemorrhage 50 46–54c [16] Dirichlet
Fatal extracranial hemorrhage 7 5.6–8.4b [12] Beta
Monthly mortality rate disability state 5.6 4.5–6.7b [19] Beta
QALYs and decrements
Atrial fibrillation 0.81 0.67819 to 0.91373c [28] Beta
Use of coumarin derivative -0.013 -0.002 to -0.033c [28] Beta
Use of new oral anticoagulant -0.006 -0.004 to -0.007c [25] Beta
Use of aspirin -0.002 0.000 to -0.006c [25] Beta
Stroke -0.1385 -0.11843 to -0.15998c [28] Beta
Transient ischemic attack -0.10322 -0.09912 to -0.11894c [28] Beta
Systemic embolism -0.1199 -0.10224 to -0.13880c [28] Beta
Myocardial infarction -0.1247 -0.10645 to -0.14356c [28] Beta
Intracranial hemorrhage -0.1814 -0.15500 to -0.20885c [28] Beta
Extracranial hemorrhage -0.06 -0.02 to -0.10c [19] Beta
Disability -0.374 -0.160 to -0.588c [19] Beta
a Assumption
b ±20 %
c 95 % Confidence interval
QALY quality-adjusted life-year
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National Institute for Health and Care Excellence (NICE)
[30, 31]. Monthly drug costs were estimated using data
from the Dutch healthcare insurance board and the NICE
report [31, 32]. Costs of the drugs and adverse events are
shown in Table 2. The data on costs were derived from
different sources. There can be differences according to
perspective, year of analysis, and the items included in the
calculations of overall costs. We tried to find the best
available data for both countries and varied these in the
sensitivity analysis. Costs were determined from a health-
care sector perspective for the year 2012 in Euros (€).
While the Dutch guidelines recommend using a societal
perspective, we used a healthcare sector perspective since
most of the cost differences were expected to be found in
this sector.
Effects were discounted at an annual rate of 1.5 % for
the Netherlands and 3.5 % for the UK, and costs at an
annual rate of 4 and 3.5 %, respectively, in accordance
with national guidelines [33, 34]. Because of the different
guidelines regarding discount rates in the two countries, we
also performed the analysis without discounting.
2.4 Base-Case and Sensitivity Analyses
Total costs and QALYs of each treatment strategy (apix-
aban, rivaroxaban, dabigatran, and the coumarin deriva-
tive) as well as the incremental cost-effectiveness ratios
(ICERs) were calculated based on means from the simu-
lations in the probabilistic sensitivity analysis (see below).
Several sensitivity analyses were also performed. First,
one-way sensitivity analyses were conducted to examine
the impact of key model parameters and assumptions on
the results. The parameters were varied over their 95 %
confidence intervals or decreased and increased by 20 % if
a confidence interval was not available (see Tables 1, 2 and
Table S3 in the ESM). The costs of events were varied over
Table 2 Country-specific model input parameters
Parameter The Netherlands UK Distribution
Base case (range) Source Base case (range) Source
Time in therapeutic range (%)
Month 1 and 2 50 (40–60a) b 50 (40–60a) b Normal
Month 3 and later 76 (63–89a) b 63 (50–76a) [14] Normal
Number of INR measurements (monthly)
Maintenance phase 1.8 (1.3–2.1c) [12] 0.83 (0.67–1a) [29] Normal
Extra during first month 4 (2–6a) a 4 (2–6a) a Normal
Costs (€)
Coumarin (monthly) 1.50 (1.20–1.80d) [32] 4.47 (3.58–5.37d) [31] Gamma
Apixaban (monthly) 68 (55–82d) [32] 82 (66–98d) [31] Gamma
Rivaroxaban (monthly) 64 (51–77d) [32] 78 (63–94d) [31] Gamma
Dabigatran (monthly) 68 (55–82d) [32] 82 (66–98d) [31] Gamma
Aspirin (monthly) 2.83 (2.26–3.40d) [32] 3.36 (2.68–4.03d) [35] Gamma
INR measurements (per visit) 10.38 (8.30–12.46d) [30] 30.40 (24–36d) [31] Gamma
Stroke 19,652 (14,000–24,000a) [36] 14,750 (10,000–20,000a) [37] Gamma
Transient ischemic attack 949 (750–1,150a) [38] 1,115 (850–1,350a) [39] Gamma
Systemic embolism 990 (500–2,200a) [40] 2,182 (900–3,000a)) [39] Gamma
Myocardial infarction 5,021 (1,800–8,000a) [41] 1,852 (1,000–6,000a) [39] Gamma
Intracranial hemorrhage 25,047 (14,000–35,000a) [42] 14,531 (10,000–30,000) [37] Gamma
Extracranial hemorrhage 13,690 (2,000–20,000a) [43] 2,256 (1,500–15,000a) [39] Gamma
Disabilitye (monthly) 480 (200–800a) [36] 780 (400–1,000a) [37] Gamma
Discount rate (yearly, %)
Costs 4 (0–8a) [34] 3.5 (0–6a) [33] –
Effects 1.5 (0–3a) [34] 3.5 (0–6a) [33] –
a Assumption
b Own data and [12]
c Range in Dutch clinics
d ±20 %
e After stroke or intracranial hemorrhage
INR international normalized ratio
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a wider range, to take into account the potentially large
differences in costs between the two countries. Second, we
performed a probabilistic sensitivity analysis using 10,000
Monte Carlo simulations to evaluate the combined impact
of multiple model parameters on the estimated cost effec-
tiveness of the new oral anticoagulants. Dirichlet distri-
butions were used to vary the probabilities of different
outcomes of stroke and ICH (more than two possible
results). Beta distributions were used for all other proba-
bilities and QALYs, and gamma distributions for the costs.
A normal distribution was used to vary the frequency of
INR measurements, the age of the patients and the per-
centage time spent in the therapeutic INR range. A scatter
plot will be made depicting the incremental costs and
effects of every simulation.
In the UK, NICE expressed a willingness-to-pay threshold
of £20,000–30,000 per QALY gained [44]. The Dutch
guidelines do not express such a threshold because it depends
on different factors, but €20,000 was often used in previous
reimbursement decisions [45]. We therefore studied the
chance that the new oral anticoagulants would be cost
effective at thresholds of €20,000 (Dutch threshold, approx-
imately £16,317) and €36,000 (UK upper threshold, approx-
imately £30,000), but also varied this threshold over a wider
range in a cost-effectiveness acceptability curve. The cost-
effectiveness acceptability curve displays the chance that a
particular intervention is the optimal intervention (i.e., most
cost-effective one) at various willingness-to-pay thresholds.
3 Results
3.1 Base Case
Figure 2 shows the first-year incidence of the clinical
events per 100 patient-years for coumarin derivatives in the
Netherlands, coumarin derivatives in the UK, and apix-
aban, rivaroxaban, or dabigatran in both countries. All
three new oral anticoagulants had a lower stroke rate than
the coumarin derivatives. ECHs were more frequent in
rivaroxaban and dabigatran, but less frequent in apixaban
than in either of the coumarins.
Table 3 shows the results of the cost-effectiveness
analyses of the new oral anticoagulants compared with a
coumarin derivative in the Netherlands and the UK. In
the Netherlands, rivaroxaban use increased costs by
€5,681, apixaban use by €4,754, and dabigatran use by
€5,465 compared with the coumarin derivative. QALYs
were increased by 0.166, 0.365, and 0.374, respectively.
The ICER compared with the coumarin derivative was
€34,248 per QALY gained for rivaroxaban, €13,024 per
QALY gained for apixaban, and €14,626 per QALY
gained for dabigatran. When all options were taken into
account, rivaroxaban was dominated by apixaban and
dabigatran (higher costs, lower QALYs). The ICER of
dabigatran versus apixaban was €82,292 per QALY
gained.
In the UK, the incremental costs compared with cou-
marin derivatives were similar for all three new oral anti-
coagulants (€5,118–5,217). Rivaroxaban use increased
QALYs by 0.302, apixaban by 0.455, and dabigatran by
0.461. The ICERs of apixaban (€11,470 per QALY gained)
and dabigatran (€11,171 per QALY gained) were some-
what lower than that of rivaroxaban (€16,949 per QALY
gained). When all options were taken into account, riva-
roxaban (higher ICER, lower QALYs) and apixaban
(higher costs, lower QALYs) were dominated by
dabigatran.
The costs per life-year gained of rivaroxaban, apixaban,
and dabigatran were €58,835, €14,117, and €15,860,
respectively, in the Netherlands and €18,420, €11,300, and
€11,029 in the UK.
Fig. 2 First-year incidence of
clinical events per 100 patient-
years. ECH extra cranial
hemorrhage, ICH intracranial
hemorrhage, IS ischaemic
stroke, MI myocardial
infarction, SE systemic
embolism, TIA transient
ischaemic attack
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3.2 Sensitivity Analyses
Figures S1 to S6 in the ESM show the tornado diagrams
summarizing the results of the one-way sensitivity analysis.
These diagrams depict the influence of key parameters on
the ICER. In the Netherlands, the percentage time in range
(varied from 63 to 89 %) had the largest impact on the
cost-effectiveness results for all three new oral anticoagu-
lants. This parameter had a smaller impact in the UK
(varied from 50 to 76 %) where for rivaroxaban the
probability of ICH (varied from 0.33 to 0.85) had the
largest impact on the cost-effectiveness results. The costs
of adverse events did not have a large influence on the
ICER in any of the comparisons, even though these were
varied over a wide range.
In the probabilistic sensitivity analysis, the new oral
anticoagulants were more costly and more effective than
coumarins in the majority of the simulations (Fig. 3). The
mean costs and effects from the simulations were similar to
our point estimate from the deterministic analysis. Figure 4
shows the probability that any of the different oral anti-
coagulants would be the most cost-effective option in the
Netherlands or in the UK over a range of likely willing-
ness-to-pay thresholds. In the Netherlands, apixaban had
the highest chance to be the most cost-effective option at a
willingness-to-pay threshold of €20,000 or €36,000 per
QALY gained (37 and 42 %, respectively). The ICER was
below these thresholds in 28 and 38 % of the simulations
for dabigatran and in 2 and 2 % of the simulations for
rivaroxaban, respectively. In the UK, dabigatran had the
highest chance to be the most cost-effective option at a
willingness-to-pay threshold of €20,000 or €36,000 per
QALY gained (41 and 48 %, respectively). These chances
were lower for apixaban (35 and 41 %, respectively) and
rivaroxaban (5 and 4 %, respectively).
4 Discussion
Our results confirm that apixaban, rivaroxaban, and da-
bigatran are all cost-effective alternatives to warfarin in the
UK. However, in the Netherlands, the incremental costs per
QALY gained for these new oral anticoagulants are higher
and rivaroxaban could not be considered cost effective at a
willingness-to-pay threshold of €20,000 per QALY gained.
The percentage time spent in the therapeutic INR range had
an important effect on the cost-effectiveness ratio. These
results indicate that the cost effectiveness of the new oral
anticoagulants is largely dependent on the setting and
quality of local anticoagulant care facilities.
Table 3 Results of the cost-effectiveness analysis: base case
Treatment Total costs (€) Total
QALYs
D costs (€) D QALYs ICER (€/QALY gained)
The Netherlands
Coumarin
derivative
8,829
(12,411)
9.625
(11.026)
Not applicable
Rivaroxaban 14,510
(20,443)
9.791
(11.223)
5,681 (8,033)a/
dominated
0.166 (0.197)a/dominated 34,248 (40,805)a/dominated
Apixaban 13,583
(19,217)
9.990
(11.471)
4,754 (6,807)a 0.365(0.444)a 13,024 (15,315)a
Dabigatran 14,294
(22,225)
9.999
(11.482)
5,465 (7,814)a/711
(1,008)b
0.374 (0.456)a/0.009
(0.011)b
14,626 (17,151)a/82,292
(90,241)b
The UK
Coumarin
derivative
7,775
(10,504)
7.966
(10.763)
Not applicable
Rivaroxaban 12,893
(17,549)
8.268
(11.237)
5,118 (7,044)a/
dominated
0.302 (0.473)a/dominated 16,949 (14,882)a/dominated
Apixaban 12,992
(17,749)
8.421
(11.489)
5,217 (7,245)a/
dominated
0.455(0.726)a/dominated 11,470 (9,984)a/dominated
Dabigatran 12,927
(17,660)
8.427
(11.500)
5,152 (7,156)a 0.461 (0.737)a 11,172 (9,709)a
Results using the country-specific discount rates are shown. Figures in parentheses indicate non-discounted results
a Compared with coumarin derivative
b Compared with apixaban
ICER incremental cost-effectiveness ratio, QALY quality-adjusted life-year
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To our knowledge, this is the first study comparing the
cost effectiveness of the new oral anticoagulants in two
different countries with different healthcare settings.
Moreover, the cost effectiveness of these new drugs in the
Dutch setting has not been published before. For the UK,
Pink et al. [46] showed a base-case ICER for dabigatran
of £23,082 (approximately €28,000) and a 60 % chance
that this drug would be cost effective at a threshold of
£30,000. Alternatively, the base-case ICER in a study by
Kansal et al. [47] was £4,831 (approximately €5,900), and
in a study by Faria et al. [48] £7,940 (approximately
€10,000). This difference is probably caused by differ-
ences in cost and quality-of-life estimates. For example,
higher long-term costs of stroke and higher warfarin
monitoring costs were used in the study by Kansal et al.
[47] In our study, the ICER of dabigatran in the UK was
somewhere in between, at €11,400 per QALY gained. In
another study in the UK, the ICER of apixaban versus
warfarin was £11,909 (approximately €15,000) [49],
which compares to the ICER of €11,655 in our study.
Recently, a few studies investigating the cost effective-
ness of the three new oral anticoagulants together have
been published. These have focused on several different
countries, including the USA [50–52], Germany [53],
France [54], Italy [55], Norway [56], and the UK [57].
Overall, apixaban had the highest chance of being cost
effective, while rivaroxaban had the lowest chance. In the
UK study, new oral anticoagulants were compared with
standard warfarin treatment as well as pharmacogenetic-
guided warfarin treatment [57]. Apixaban remained the
Fig. 3 Scatter plots reflecting
the uncertainty in the
differences in costs and
effectiveness between the new
oral anticoagulants and
coumarins (based on
probabilistic sensitivity
analysis). QALY quality-
adjusted life-year
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most cost-effective option if compared with both warfarin
strategies.
Although we adjusted the clinical event rates from the
three trials for differences in baseline risks, uncertainty
remains about the comparison between the three different
new oral anticoagulants. Because the three drugs have not
been studied in a head-to-head trial, it was not possible to
investigate the cost effectiveness of these drugs using
information from a direct comparison. Another limitation is
that the follow-up in the three trials was approximately
2 years. We extrapolated these data to a lifetime horizon,
assuming the event rates would remain stable after 2 years.
Lastly, because no official cost-effectiveness threshold
exists in the Netherlands, it is difficult to state whether or
not a new therapy will be considered cost effective. This
threshold is influenced by several factors, for example life
expectancy or disease severity [45].
In this study, we used a healthcare sector perspective,
while the Dutch guidelines recommend using a societal
perspective. This will not have a large influence on the
results because our study involves older patients and
therefore no difference in productivity losses was expected.
However, travel costs and time costs for the patients can
differ between coumarin derivatives and the new oral
anticoagulants because coumarin derivatives require fre-
quent INR measurements while the new oral anticoagulants
do not. We estimated that these costs could increase the
costs of coumarin derivatives by approximately €100 per
year. Addition of these costs does not alter the conclusions
of our study, although it makes the use of coumarin
derivatives somewhat less favorable.
Our results indicate that country- or healthcare setting-
specific analyses are important to study the cost effec-
tiveness of new oral anticoagulants compared with
Fig. 4 Cost-effectiveness
acceptability curve for the
Netherlands and the UK. QALY
quality-adjusted life-year
Cost Effectiveness of New Oral Anticoagulants in Two Different European Healthcare Settings 459
coumarin derivatives. Because of differences in costs of the
drugs or differences in the treatment costs of clinical
events, the cost effectiveness of drugs can differ between
countries. But more important in this case is the difference
in healthcare setting and quality of the treatment with
coumarin derivatives. In the Dutch setting of anticoagulant
clinics, with a high percentage time spent in the therapeutic
INR range, the new drugs are less cost effective than in the
English setting where patients are treated by the general
practitioner and spend less time in the therapeutic INR
range. The difference between the two countries is largely
driven by the difference in INR control. In the sensitivity
analysis, we show that if the percentage time in therapeutic
INR range in the UK were higher, the ICER for the new
anticoagulants would increase. However, as shown in the
tornado diagrams, the ICER of dabigatran and apixaban in
the UK would not reach the £30,000 threshold (approxi-
mately €36,000) even if the percentage time in therapeutic
range were as high as in the Netherlands (76 %). The ICER
for rivaroxaban would be just above €40,000 with a per-
centage time in therapeutic range as high as in the Neth-
erlands. A strength of this study is that we compared the
new oral anticoagulants with coumarin derivatives in two
different countries using the same model and analyses,
making the results easier to compare than the results from
two different studies. In the UK, the USA, and several
other countries, warfarin is the most frequently used cou-
marin derivative [58]. In the Netherlands, this drug is not
registered and therefore acenocoumarol is the most fre-
quently used coumarin derivative there. For this reason, we
used data on warfarin to model the costs and effects of
coumarin derivatives in the UK and data on acenocoumarol
for the Netherlands. Because different coumarins were
used in the two countries, the two comparisons are not
identical, but based on clinical practice. We believe this
would not cause differences in our results because of the
similarity in mechanism and pharmacokinetic characteris-
tics between the different coumarins [15] and because we
adjusted for differences in percentage time in therapeutic
range. However, a limitation in the comparison between
the two countries is that the therapeutic INR range in the
UK (and many other countries) is 2.0–3.0, while this range
is 2.0–3.5 in the Netherlands. However, many differences
between the countries are captured by looking at the dif-
ferences in time spent in therapeutic INR range. As we
combined this metric with the risks of events associated
with different INR ranges, we were able to adjust for
quality of coumarin anticoagulant care and could therefore
use country-specific event rates.
Another limitation is the use of clinical trial data,
instead of real-world data, to model the incidence of events
with the new oral anticoagulants. The cost effectiveness of
the new oral anticoagulants might be overestimated in this
study, because we used data from the three large ran-
domized trials, which might not represent the real-world
population. Real-world data might better represent the
population under study and, in this way, the cost effec-
tiveness could be estimated more reliably. These data are
not available yet and therefore we recommend that the cost
effectiveness be re-assessed once the effectiveness of the
new drugs can be studied with real-world data.
In the UK, apixaban, rivaroxaban, and dabigatran all
appear to be cost-effective alternatives to warfarin,
increasing health at acceptable costs. While all three new
oral anticoagulants also lead to improved health in the
Netherlands, the incremental costs of rivaroxaban are
higher than what may be regarded as acceptable. In con-
trast, dabigatran and apixaban seem to be cost-effective
options in the Netherlands. In both countries, the use of
new oral anticoagulants will impact the healthcare budget.
Also, the use of anticoagulation clinics might decrease
when the new drugs are used more frequently. Whether it is
better to spend the budget on new oral anticoagulants or on
improving the quality of current care with coumarin
derivatives (by for example pharmacogenetic-guided dos-
ing) is an interesting question for debate.
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